Renaissance Technologies’s Nabriva Therapeutics plc Ordinary Shares Ireland NBRV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-22,861
| Closed | -$35K | – | 4323 |
|
|
2023
Q2 | $35K | Sell |
22,861
-500
| -2% | -$794 | ﹤0.01% | 3679 |
|
|
2023
Q1 | $41K | Buy |
23,361
+300
| +1% | +$504 | ﹤0.01% | 3706 |
|
|
2022
Q4 | $44K | Buy |
23,061
+2,500
| +12% | +$5.52K | ﹤0.01% | 3823 |
|
|
2022
Q3 | $43K | Sell |
20,561
-11,277
| -35% | -$47.5K | ﹤0.01% | 3796 |
|
|
2022
Q2 | $145K | Buy |
31,838
+16,086
| +102% | +$105K | ﹤0.01% | 3753 |
|
|
2022
Q1 | $165K | Sell |
15,752
-3,100
| -16% | -$37.7K | ﹤0.01% | 3696 |
|
|
2021
Q4 | $282K | Buy |
18,852
+10,137
| +116% | +$240K | ﹤0.01% | 3368 |
|
|
2021
Q3 | $259K | Sell |
8,715
-26,061
| -75% | -$736K | ﹤0.01% | 3127 |
|
|
2021
Q2 | $1.17M | Buy |
34,776
+30,232
| +665% | +$1.13M | ﹤0.01% | 2591 |
|
|
2021
Q1 | $189K | Sell |
4,544
-9,150
| -67% | -$568K | ﹤0.01% | 3162 |
|
|
2020
Q4 | $829K | Buy |
13,694
+13,572
| +11,125% | +$1.47M | ﹤0.01% | 2600 |
|
|
2020
Q3 | $16K | Buy |
+122
| New | +$20.4K | ﹤0.01% | 3328 |
|
|
2020
Q2 | – | Sell |
-910
| Closed | -$131K | – | 3909 |
|
|
2020
Q1 | $131K | Sell |
910
-3,409
| -79% | -$1.04M | ﹤0.01% | 3180 |
|
|
2019
Q4 | $1.43M | Sell |
4,319
-1,198
| -22% | -$549K | ﹤0.01% | 2473 |
|
|
2019
Q3 | $2.76M | Buy |
5,517
+320
| +6% | +$180K | ﹤0.01% | 2102 |
|
|
2019
Q2 | $3.16M | Buy |
5,197
+1,774
| +52% | +$1.09M | ﹤0.01% | 2095 |
|
|
2019
Q1 | $2.09M | Buy |
3,423
+1,302
| +61% | +$710K | ﹤0.01% | 2287 |
|
|
2018
Q4 | $774K | Buy |
2,121
+980
| +86% | +$527K | ﹤0.01% | 2696 |
|
|
2018
Q3 | $770K | Buy |
1,141
+1,090
| +2,137% | +$773K | ﹤0.01% | 2712 |
|
|
2018
Q2 | $45K | Sell |
51
-67
| -57% | -$76.7K | ﹤0.01% | 3196 |
|
|
2018
Q1 | $148K | Sell |
118
-612
| -84% | -$905K | ﹤0.01% | 3221 |
|
|
2017
Q4 | $1.09M | Buy |
+730
| New | +$1.15M | ﹤0.01% | 2635 |
|
|
2017
Q1 | – | Sell |
-69
| Closed | -$103K | – | 3495 |
|
|
2016
Q4 | $103K | Buy |
+69
| New | +$91.6K | ﹤0.01% | 3100 |
|
Renaissance Technologies's NBRV Position: Q3 2023 in Review
Renaissance Technologies sold out of Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) in Q3 2023, closing a stake of 22,861 shares — an estimated $35K sold.
Renaissance Technologies first reported a position in NBRV in Q4 2016 and held it in 23 quarters. The position peaked at $3.16M in Q2 2019. 0 funds tracked by Wall St. Rank hold NBRV as of Q3 2023.
- Renaissance Technologies reported no remaining Nabriva Therapeutics plc Ordinary Shares Ireland position as of Q3 2023 after selling out during the quarter.
- Renaissance Technologies sold 22,861 Nabriva Therapeutics plc Ordinary Shares Ireland shares in Q3 2023, an estimated $35K.
- Renaissance Technologies first reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland in Q4 2016 and held it in 23 quarters.
- Renaissance Technologies's Nabriva Therapeutics plc Ordinary Shares Ireland position peaked at $3.16M in Q2 2019.
- 0 funds tracked by Wall St. Rank held Nabriva Therapeutics plc Ordinary Shares Ireland as of Q3 2023.
Based on Renaissance Technologies's 13F filing for Q3 2023, filed 14 Nov 2023.